## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

## **SCHEDULE 13G**

Under the Securities Exchange Act of 1934 (Amendment No. 1)\*

# Verrica Pharmaceuticals Inc.

(Name of Issuer)

Common Stock, \$0.0001 par value per share (Title of Class of Securities)

> 92511W108 (CUSIP Number)

December 31, 2018 (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 $\Box$  Rule 13d-1(b)

Z Rule 13d-1(c)

 $\Box$  Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

## CUSIP No. 92511W108

1 NAMES OF REPORTING PERSONS						
Percept	ve Advisors LLC					
2 CHECK	2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)					
(a) □	(b) 🗆					
3 SEC US	3 SEC USE ONLY					
J SLC OL	5 SEC USE ONE I					
4 CITIZENSHIP OR PLACE OF ORGANIZATION						
Delawa						
	5 SOLE VOTING POWER					
NUMBER						
SHARE						
BENEFICIALLY						
OWNED EACH						
REPORT	NG					
PERSO WITH						
*****	8 SHARED DISPOSITIVE POWER					
	3,410,412					
9 AGGR	EGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON					
	3,410,412     10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)					
10 CHEC.	X BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)					
11 PERCI	NT OF CLASS REPRESENTED BY AMOUNT IN ROW 9					
12.20/						
	13.3%   12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)					
IA						

## CUSIP No. 92511W108

1 NAMES OF REPORTING PERSONS					
Joseph Edelman					
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)					
(a) $\square$ (b) $\square$					
3 SEC USE ONLY					
4 CITIZENSHIP OR PLACE OF ORGANIZATION					
United States of America					
5 SOLE VOTING POWER					
NUMBER OF SHARES 0   6 SHARED VOTING POWER					
BENEFICIALLY					
OWNED BY 3,410,412					
EACH 7 SOLE DISPOSITIVE POWER					
REPORTING					
PERSON					
WITH: 8 SHARED DISPOSITIVE POWER					
3,410,412					
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON					
3,410,412					
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)					
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9					
13.3%					
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)					
IN					

## CUSIP No. 92511W108

1	1 NAMES OF REPORTING PERSONS					
	Percentive Lit	èS	siences Master Fund I td			
2	Perceptive Life Sciences Master Fund, Ltd.     2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)					
2	(a) $\Box$ (b) $\Box$					
	$(a) \square (0)$					
3	3 SEC USE ONLY					
4	4 CITIZENSHIP OR PLACE OF ORGANIZATION					
4	4 CITIZENSHIP OR PLACE OF ORGANIZATION					
	Cayman Islands					
		5	SOLE VOTING POWER			
			0			
Ν	UMBER OF SHARES	6	SHARED VOTING POWER			
BENEFICIALLY						
OWNED BY3,410,412EACH7SOLE DIS			3,410,412			
			SOLE DISPOSITIVE POWER			
ł	REPORTING PERSON					
	WITH:		0			
		8	SHARED DISPOSITIVE POWER			
			3,410,412			
9	AGGREGAT	ΕA	MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
	3,410,412					
10						
10	CILCKDOA		THE AGOREGATE AWOUNT IN NOW () EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)			
11	11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9					
	13.3%					
12						
12	111L OI KL	1 01				
	СО					
	•					

#### Item 1(a). <u>Name of Issuer</u>:

Verrica Pharmaceuticals, Inc. (the "Issuer")

#### Item 1(b). Address of Issuer's Principal Executive Offices:

450 East 29th Street

New York, New York 10016

#### Item 2(a). <u>Names of Persons Filing</u>:

The names of the persons filing this report (collectively, the "Reporting Persons") are: Perceptive Advisors LLC ("Perceptive Advisors") Joseph Edelman ("Mr. Edelman") Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund")

#### Item 2(b). Address of Principal Business Office or, if None, Residence:

The address of the principal business office of each of the Reporting Persons is: 51 Astor Place, 10th Floor New York, NY 10003

#### Item 2(c). <u>Citizenship</u>:

Perceptive Advisors is a Delaware limited liability company Mr. Edelman is a United States citizen The Master Fund is a Cayman Islands corporation

#### Item 2(d). <u>Title of Class of Securities</u>:

Common Stock, \$0.0001 par value per share ("Common Stock")

Item 2(e). <u>CUSIP Number</u>:

92511W108

## Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: Not applicable.

#### Item 4. <u>Ownership</u>.

The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages reported are based on 25,696,371 outstanding shares of Common Stock, as reported in the Issuer's Form 10-Q filed on November 7, 2018.

Neither Perceptive Advisors nor Mr. Edelman directly holds any shares of Common Stock. The Master Fund directly holds 3,410,412 shares of Common Stock. Perceptive Advisors serves as the investment manager to the Master Fund and may be deemed to beneficially own the securities directly held by the Master Fund. Mr. Edelman is the managing member of Perceptive Advisors and may be deemed to beneficially own the securities directly held by the Master Fund.

#### Item 5. <u>Ownership of Five Percent or Less of a Class</u>.

If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following  $\Box$ .

#### Item 6. <u>Ownership of More than Five Percent on Behalf of Another Person</u>.

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not applicable.

Item 8. <u>Identification and Classification of Members of the Group</u>. Not applicable.

Item 9. <u>Notice of Dissolution of Group</u>.

Not applicable.

#### Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

### SIGNATURE

After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Date: February 14, 2019

PERCEPTIVE ADVISORS LLC

By: /s/ Joseph Edelman

Name: Joseph Edelman Title: Managing Member

/s/ Joseph Edelman JOSEPH EDELMAN

PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.

By: Perceptive Advisors LLC

By: /s/ Joseph Edelman

Name: Joseph Edelman Title: Managing Member

#### AGREEMENT

The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934.

Date: February 14, 2019

PERCEPTIVE ADVISORS LLC

By: /s/ Joseph Edelman

Name: Joseph Edelman Title: Managing Member

/s/ Joseph Edelman JOSEPH EDELMAN

PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.

By: Perceptive Advisors LLC

By: <u>/s/ Joseph Edelman</u> Name: Joseph Edelman Title: Managing Member